DelveInsight’s Community-acquired Bacterial Pneumonia Market Insights report includes a comprehensive understanding of current treatment practices, Community-acquired Bacterial Pneumonia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.
Key Takeaways from the Community-acquired Bacterial Pneumonia Market
Discover more about therapies set to grab major Community-acquired Bacterial Pneumonia market share @ Community-acquired Bacterial Pneumonia Market Landscape
Community-acquired Bacterial Pneumonia Overview
Community-acquired Bacterial Pneumonia (CABP) is a common, severe infection of the lung parenchyma. It is a leading cause of death in adults. It is one of the most common respiratory diseases among the various infections that cause sepsis. Community-acquired Bacterial Pneumonia most commonly caused by Streptococcus pneumoniae in adults worldwide. Haemophilus influenzae and Mycoplasma pneumoniae are two other common bacteria that cause Community-acquired Pneumonia (CAP). Chlamydia and mycoplasma pneumonia is frequently clinically indistinguishable from other types of pneumonia.
The CABP symptoms include malaise, chills, rigor, fever, cough, dyspnea, and chest pain. Coughing is usually productive in older children and adults but dry in infants, young children, and the elderly. Dyspnea is usually mild and exertional, and it is almost never present at rest.
Community-acquired Bacterial Pneumonia Epidemiology Segmentation
The Community-acquired Bacterial Pneumonia Market Report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
Download report to understand which factors are driving CABP infection epidemiology trends @ Community-acquired Bacterial Pneumonia Epidemiological Insights
Community-acquired Bacterial Pneumonia Market
Although the majority of patients with Community-acquired Pneumonia are treated empirically, but the best treatment option remains unknown. The antibiotics govern the Community-Acquired Bacterial Pneumonia treatment landscape. Nuzyra (omadacycline), Baxdela (delafloxacin), and Xenleta (lefamulin) are some of the drugs approved for the Community-Acquired Bacterial Pneumonia treatment. In addition, Recarbrio (Cilastatin/imipenem/relebactam), Fetroja (cefiderocol), Avycaz (ceftazidime-avibactam), Vibativ (telavancin), and Zerbaxa (ceftolozane + tazobactam) are among the drugs approved for hospital-acquired/ventilator-associated bacterial pneumonia (HABP).
Moreover, in individuals 18 years of age and older, a vaccine such as Vaxneuvance is recommended for active immunization to prevent invasive disease and pneumonia caused by Streptococcus pneumoniae.
Furthermore, Community-acquired Pneumonia treatment has become difficult due to changing safety profiles and efficacy of well-established antibiotics, as well as a lack of new therapeutic options.
Discover more about therapy set to grab substantial Community-acquired Bacterial Pneumonia market share @ Community-acquired Bacterial Pneumonia Treatment
Community-acquired Bacterial Pneumonia Pipeline Therapies and Key Players
Scope of the Community-acquired Bacterial Pneumonia Market Report
Table of Contents
1.
Key Insights
2.
Report Introduction
3.
Community-acquired Bacterial Pneumonia Market Overview at a Glance
4.
Executive Summary
5.
Disease Background and Overview
6.
Treatment and Management
7.
Epidemiology and Patient Population
8.
Patient Journey
9.
Community-acquired Bacterial Pneumonia Marketed Therapies
10.
Emerging Drugs
11.
Other Therapies: Generics
12.
7 Major Market Analysis
13.
Community-acquired Bacterial Pneumonia Market Outlook
14.
KOL Views
15.
Unmet Needs
16.
SWOT Analysis
17.
Appendix
18.
DelveInsight Capabilities
19.
Disclaimer
20.
About DelveInsight
Discover more about the future Community-acquired Bacterial Pneumonia market share of treatment therapies @ Community-acquired Bacterial Pneumonia Treatment Market
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting